A cohort study involving commercially insured patients, reflective of real-world scenarios, demonstrated that users of SGLT-2 inhibitors exhibited higher rates of PAD, osteomyelitis, and lower limb ulcers when compared to individuals using metformin, sulfonylureas, or thiazolidinediones. This evidence concerns the gene SLC5A2 and peripheral arterial disease.